Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic, outcome |
This site uses Akismet to reduce spam. Learn how your comment data is processed.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK
The abstract indicates that “The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.” What was this subset?
Dear Paul:
If you look at the original announcement from Bristol-Meyers Squibb (see link above), you will see that there was a small but statistically non-significant difference in the outcomes of the men on ipilimumab as opposed to the ones on the placebo, which does indeed “suggest antitumor activity” in a subset of patients, but as far as I am aware no one has been able to identify that subset of patients with accuracy.